NEW YORK (GenomeWeb) – Transgenomic announced today that it has sold its ion chromatography product line and all related assets to Edge BioSystems for roughly $2.1 million in cash.

Under the deal, Edge, which manufactures and distributes DNA sequencing sample preparation and clean-up products, acquired all of Transgenomics' ion chromatography products, licenses, technology, know-how, trademarks, and inventory.

Additional terms of the arrangement were not disclosed.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.